Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2C19, Cytochrome P450 2D6, Cytochrome P450 3A4 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4)
- Target
- CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4
- Molecular classification
- Enzyme, Oxidoreductase, Heme-thiolate monooxygenase, Phase I drug metabolism enzyme, Membrane-associated protein
01
Overview
The cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are heme-containing oxidoreductase enzymes predominantly located in the liver and are responsible for the metabolism of roughly 70–90% of clinically used drugs[5][7]. They catalyze phase I metabolic reactions, primarily oxidations, leading to increased drug solubility or bioactivation/inactivation. Individual variation in these enzymes, due to genetic polymorphisms or drug-induced expression/inhibition, underpins much of the observed variability in drug efficacy and adverse reactions, and they are crucial in predicting drug interactions in clinical medicine[1][3][4][5][7].
- Other names
- P450 1A2CYPIA2P450 2C9CYPIIC9P450 2C19CYPIIC19P450 2D6CYPIID6P450 3A4CYP3A subfamily member 4P450 IIIA4
02
Mechanism of action
Substrate oxidation (hydroxylation, dealkylation, epoxidation, etc.) by monooxygenase activity\nModulation via inhibition (competitive/noncompetitive/blocking) by specific drugs\nModulation via induction (increased expression/activity) by other agents or compounds
03
Biological functions
Drug metabolismDetoxification of xenobioticsEndogenous compound metabolism (e.g., steroids, fatty acids)Oxidation and biotransformation reactionsMetabolism of carcinogens
04
Disease associations
Adverse drug reactionsDrug-drug interactionsCancer (through activation/inactivation of procarcinogens)Variability in drug efficacy and toxicityOther diseases affected by medication metabolism
05
Safety considerations
Interindividual variability leading to unpredictable pharmacokinetics and toxicitySerious drug-drug interactions (e.g., inhibition/induction leading to toxicity or treatment failure)Genetic polymorphisms resulting in poor or ultra-rapid metabolism for specific drugsRisk of adverse drug reactions (e.g., bleeding with warfarin, serotonin syndrome with SSRI/CYP interactions)Carcinogen bioactivation
06
Interacting drugs
caffeine
32 more in the full profile.
07
Biomarkers
Genetic polymorphisms (e.g., CYP2C9*2, CYP2D6*10, CYP2C19*2)Enzyme activity phenotyping (based on probe substrates, e.g., caffeine for CYP1A2)Drug and metabolite plasma levels for monitoring exposure and efficacy (e.g., warfarin for CYP2C9)
Beyond the preview
Go deeper on Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2C19, Cytochrome P450 2D6, Cytochrome P450 3A4 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2C19, Cytochrome P450 2D6, Cytochrome P450 3A4 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).